📉 The Financial Deep Dive
Poly Medicure Limited unveiled its Q3 FY26 financial results, showcasing a commendable 16.4% Year-on-Year (YoY) revenue growth to ₹493.7 Cr. This top-line expansion was a balanced effort, with international sales rising 16.6% and domestic sales growing 16.2%. The nine-month period (9M FY26) also saw a healthy 9.1% YoY increase in consolidated revenue, reaching ₹1340.7 Cr.
However, the bottom line presented a mixed picture. Consolidated Profit After Tax (PAT) for Q3 FY26 experienced a significant 16.9% YoY decline, settling at ₹70.8 Cr. This downturn was primarily attributed to extraordinary expenses totalling ₹13.3 Cr, comprising ₹6.8 Cr for the Revised Labour Code and ₹6.5 Cr in acquisition-related costs for PendraCare and Citieffe groups.
On a standalone basis, revenue growth was more modest at 1.9% YoY to ₹418.9 Cr, with PAT falling 8.0% YoY to ₹78.4 Cr.
Operating EBITDA for consolidated operations in Q3 FY26 saw a 2.8% YoY increase to ₹119.4 Cr. Despite this, the EBITDA margin compressed by 319 basis points to 24.2% when excluding acquisition costs, indicating pressure on profitability. For 9M FY26, consolidated Operating EBITDA grew 2.7% YoY to ₹345.3 Cr, with a margin of 25.8%, which the company noted was within its guidance range of 25-27%.
🚀 Strategic Analysis & Impact
The company has successfully integrated PendraCare Group and Citieffe Group, a move impacting the current quarter's financials. Poly Medicure continues to bolster its product pipeline, launching 19 new products in 9M FY26. A significant development is the DCGI approval for its Intravenous Lithotripsy (IVL) System and Drug Eluting Balloon (DEB).
The RisoR stent clinical study is progressing well, with over 200 patients enrolled, signalling potential for future cardiovascular product offerings.
🚩 Risks & Outlook
Risks include the impact of one-off expenses on short-term profitability and the inherent integration challenges of acquisitions. Margin pressure, if sustained, could affect investor sentiment.
The Forward View: Investors should closely monitor the performance of the newly acquired entities and the commercial rollout of the recently approved IVL and DEB systems. The company's robust liquidity position of ₹839.8 Cr and capital expenditure of ₹234 Cr in 9M FY26 indicate continued investment in growth. Management's focus on R&D and new product launches, coupled with positive commentary on the MedTech sector's prospects due to trade deals and budget expectations, suggests a strategic long-term direction despite near-term profitability headwinds.